热门资讯> 正文
Corbus Pharmaceuticals每股收益为-0.83美元,击败0.26美元
2024-05-08 01:13
- Corbus Pharmaceuticals press release (NASDAQ:CRBP): Q1 EPS of -$0.83 beats by $0.26.
- The $116 million of additional capital extends the Company’s cash runway through Q1, 2027.
More on Corbus Pharmaceuticals
- Neutral On Corbus Pharmaceuticals' Financials And Clinical Progress In Oncology
- Seeking Alpha’s Quant Rating on Corbus Pharmaceuticals
- Historical earnings data for Corbus Pharmaceuticals
- Financial information for Corbus Pharmaceuticals
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。